Cargando…
Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
Significant progress has been made in our understanding of the neurobiology of Parkinson’s disease (PD). Post-mortem studies are an important step and could help to comprehend not only the progression of motor symptoms, but also the involvement of other clinical domains, including cognition, behavio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628799/ https://www.ncbi.nlm.nih.gov/pubmed/34842741 http://dx.doi.org/10.3390/geriatrics6040110 |
_version_ | 1784607073902788608 |
---|---|
author | Lauretani, Fulvio Ruffini, Livia Testa, Crescenzo Salvi, Marco Scarlattei, Mara Baldari, Giorgio Zucchini, Irene Lorenzi, Beatrice Cattabiani, Chiara Maggio, Marcello |
author_facet | Lauretani, Fulvio Ruffini, Livia Testa, Crescenzo Salvi, Marco Scarlattei, Mara Baldari, Giorgio Zucchini, Irene Lorenzi, Beatrice Cattabiani, Chiara Maggio, Marcello |
author_sort | Lauretani, Fulvio |
collection | PubMed |
description | Significant progress has been made in our understanding of the neurobiology of Parkinson’s disease (PD). Post-mortem studies are an important step and could help to comprehend not only the progression of motor symptoms, but also the involvement of other clinical domains, including cognition, behavior and impulse control disorders (ICDs). The correlation of neuropathological extension of the disease with the clinical stages remains challenging. Molecular imaging, including positron emission tomography (PET) and single photon computed tomography (SPECT), could allow for bridging the gap by providing in vivo evidence of disease extension. In the last decade, we have observed a plethora of reports describing improvements in the sensitivity of neuroimaging techniques. These data contribute to increasing the accuracy of PD diagnosis, differentiating PD from other causes of parkinsonism and also obtaining a surrogate marker of disease progression. FDG-PET has been used to measure cerebral metabolic rates of glucose, a proxy for neuronal activity, in PD. Many studies have shown that this technique could be used in early PD, where reduced metabolic activity correlates with disease progression and could predict histopathological diagnosis. The aim of this work is to report two particular cases of PD in which the assessment of brain metabolic activity (from FDG-PET) has been combined with clinical aspects of non-motor symptoms. Integration of information on neuropsychological and metabolic imaging allows us to improve the treatment of PD patients irrespective of age. |
format | Online Article Text |
id | pubmed-8628799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86287992021-11-30 Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age Lauretani, Fulvio Ruffini, Livia Testa, Crescenzo Salvi, Marco Scarlattei, Mara Baldari, Giorgio Zucchini, Irene Lorenzi, Beatrice Cattabiani, Chiara Maggio, Marcello Geriatrics (Basel) Case Report Significant progress has been made in our understanding of the neurobiology of Parkinson’s disease (PD). Post-mortem studies are an important step and could help to comprehend not only the progression of motor symptoms, but also the involvement of other clinical domains, including cognition, behavior and impulse control disorders (ICDs). The correlation of neuropathological extension of the disease with the clinical stages remains challenging. Molecular imaging, including positron emission tomography (PET) and single photon computed tomography (SPECT), could allow for bridging the gap by providing in vivo evidence of disease extension. In the last decade, we have observed a plethora of reports describing improvements in the sensitivity of neuroimaging techniques. These data contribute to increasing the accuracy of PD diagnosis, differentiating PD from other causes of parkinsonism and also obtaining a surrogate marker of disease progression. FDG-PET has been used to measure cerebral metabolic rates of glucose, a proxy for neuronal activity, in PD. Many studies have shown that this technique could be used in early PD, where reduced metabolic activity correlates with disease progression and could predict histopathological diagnosis. The aim of this work is to report two particular cases of PD in which the assessment of brain metabolic activity (from FDG-PET) has been combined with clinical aspects of non-motor symptoms. Integration of information on neuropsychological and metabolic imaging allows us to improve the treatment of PD patients irrespective of age. MDPI 2021-11-10 /pmc/articles/PMC8628799/ /pubmed/34842741 http://dx.doi.org/10.3390/geriatrics6040110 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Lauretani, Fulvio Ruffini, Livia Testa, Crescenzo Salvi, Marco Scarlattei, Mara Baldari, Giorgio Zucchini, Irene Lorenzi, Beatrice Cattabiani, Chiara Maggio, Marcello Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age |
title | Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age |
title_full | Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age |
title_fullStr | Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age |
title_full_unstemmed | Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age |
title_short | Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age |
title_sort | cognitive and behavior deficits in parkinson’s disease with alteration of fdg-pet irrespective of age |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628799/ https://www.ncbi.nlm.nih.gov/pubmed/34842741 http://dx.doi.org/10.3390/geriatrics6040110 |
work_keys_str_mv | AT lauretanifulvio cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT ruffinilivia cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT testacrescenzo cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT salvimarco cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT scarlatteimara cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT baldarigiorgio cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT zucchiniirene cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT lorenzibeatrice cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT cattabianichiara cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage AT maggiomarcello cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage |